Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer

NCT01414296 is registered in ClinicalTrials.gov with Progenics Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01414296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01414296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer
Lead sponsor
Progenics Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
November 30, 2013
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer